SequelSEC

Silexion Therapeutics Corp SLXN

Biological Products, (No Diagnostic Substances) · CIK 0002022416 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$14.13M
Fiscal year ended 2026-06-30
Free cash flow
-$12.43M
Fiscal year ended 2026-06-30

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio2.41x31th

Silexion Therapeutics Corp (SLXN) reported net income of -$13.96M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Silexion Therapeutics Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Silexion Therapeutics Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
RevenueUnavailable
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$14.13M
Net income-$13.96M
Research & development$9.11M
Weighted-average diluted sharesUnavailable
Pretax income-$13.96M
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$5.01M
Selling & marketingUnavailable

Balance

Silexion Therapeutics Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$2.23M
Total assets$4.25M
Current assets$3.74M
Total liabilities$4.20M
Current liabilities$3.98M
Total equity incl. NCI$44.00K
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

Silexion Therapeutics Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$12.43M
Capital expenditures$2.00K
Investing cash flow-$8.00K
Financing cash flow$11.23M
Net change in cashUnavailable
Stock-based compensation$618.00K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Silexion Therapeutics Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$12.43M
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.94x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SLXN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-17View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.